Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy
Abstract Neoadjuvant chemotherapy (NAC) is well-established for locally advanced breast cancer, even in the early stages, especially in HER2-positive and triple-negative cases. However, the effect of chronologic age on NAC response remains controversial. This study investigates the efficacy and outc...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-93203-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850095011911172096 |
|---|---|
| author | Eda Caliskan Yildirim Elif Atag Huseyin Salih Semiz Olcun Umit Unal Mehmet Uzun Suleyman Ozkan Aksoy Merih Guray Durak Aziz Karaoglu |
| author_facet | Eda Caliskan Yildirim Elif Atag Huseyin Salih Semiz Olcun Umit Unal Mehmet Uzun Suleyman Ozkan Aksoy Merih Guray Durak Aziz Karaoglu |
| author_sort | Eda Caliskan Yildirim |
| collection | DOAJ |
| description | Abstract Neoadjuvant chemotherapy (NAC) is well-established for locally advanced breast cancer, even in the early stages, especially in HER2-positive and triple-negative cases. However, the effect of chronologic age on NAC response remains controversial. This study investigates the efficacy and outcomes of NAC in older patients with breast cancer, compared to a younger cohort, to address the current knowledge gap. 535 patients who received NAC followed by curative surgery from 2010 to 2021 were retrospectively analyzed. We evaluated breast and axillary downstaging, pathologic complete response (pCR), and post-treatment toxicities. Data were stratified by age, with patients aged 65 years and older representing the older group. Anthracycline-based chemotherapy was prevalent (97.6%) and favored younger patients who received a dose-dense anthracycline regimen (71.7% vs. 38.5%, p < 0.001). Surgical outcomes, breast and axillary downstaging, and the pathologic complete response showed no age-related differences. Grade 3–4 toxicity was higher in older patients (71% vs. 46.4%, p < 0.01). Older patients treated with NAC achieve comparable outcomes to younger patients, supporting personalized treatment. Chronologic age should not dictate treatment decisions, emphasizing the need for comprehensive evaluation for optimal geriatric patient care. |
| format | Article |
| id | doaj-art-96dbd0feef894d42876b63ed38c4f407 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-96dbd0feef894d42876b63ed38c4f4072025-08-20T02:41:32ZengNature PortfolioScientific Reports2045-23222025-03-011511810.1038/s41598-025-93203-1Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapyEda Caliskan Yildirim0Elif Atag1Huseyin Salih Semiz2Olcun Umit Unal3Mehmet Uzun4Suleyman Ozkan Aksoy5Merih Guray Durak6Aziz Karaoglu7Department of Internal Medicine, Division of Medical Oncology, Dokuz Eylul UniversityDepartment of Internal Medicine, Division of Medical Oncology, Dokuz Eylul UniversityDepartment of Internal Medicine, Division of Medical Oncology, Dokuz Eylul UniversityDepartment of Internal Medicine, Health Sciences University Izmir Faculty of MedicineDepartment of Internal Medicine, Division of Medical Oncology, Dokuz Eylul UniversityDepartment of General Surgery, Dokuz Eylul UniversityDepartment of Pathology, Dokuz Eylul UniversityDepartment of Internal Medicine, Division of Medical Oncology, Dokuz Eylul UniversityAbstract Neoadjuvant chemotherapy (NAC) is well-established for locally advanced breast cancer, even in the early stages, especially in HER2-positive and triple-negative cases. However, the effect of chronologic age on NAC response remains controversial. This study investigates the efficacy and outcomes of NAC in older patients with breast cancer, compared to a younger cohort, to address the current knowledge gap. 535 patients who received NAC followed by curative surgery from 2010 to 2021 were retrospectively analyzed. We evaluated breast and axillary downstaging, pathologic complete response (pCR), and post-treatment toxicities. Data were stratified by age, with patients aged 65 years and older representing the older group. Anthracycline-based chemotherapy was prevalent (97.6%) and favored younger patients who received a dose-dense anthracycline regimen (71.7% vs. 38.5%, p < 0.001). Surgical outcomes, breast and axillary downstaging, and the pathologic complete response showed no age-related differences. Grade 3–4 toxicity was higher in older patients (71% vs. 46.4%, p < 0.01). Older patients treated with NAC achieve comparable outcomes to younger patients, supporting personalized treatment. Chronologic age should not dictate treatment decisions, emphasizing the need for comprehensive evaluation for optimal geriatric patient care.https://doi.org/10.1038/s41598-025-93203-1Breast cancerNeoadjuvant chemotherapyPCROlder patientsDownstaging |
| spellingShingle | Eda Caliskan Yildirim Elif Atag Huseyin Salih Semiz Olcun Umit Unal Mehmet Uzun Suleyman Ozkan Aksoy Merih Guray Durak Aziz Karaoglu Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy Scientific Reports Breast cancer Neoadjuvant chemotherapy PCR Older patients Downstaging |
| title | Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy |
| title_full | Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy |
| title_fullStr | Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy |
| title_full_unstemmed | Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy |
| title_short | Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy |
| title_sort | achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy |
| topic | Breast cancer Neoadjuvant chemotherapy PCR Older patients Downstaging |
| url | https://doi.org/10.1038/s41598-025-93203-1 |
| work_keys_str_mv | AT edacaliskanyildirim achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT elifatag achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT huseyinsalihsemiz achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT olcunumitunal achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT mehmetuzun achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT suleymanozkanaksoy achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT merihguraydurak achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy AT azizkaraoglu achievingtreatmentgoalsinolderbreastcancerpatientsreceivingneoadjuvantchemotherapy |